AGE-RELATED MACULAR DEGENERATION (ARMD)
Clinical trials for AGE-RELATED MACULAR DEGENERATION (ARMD) explained in plain language.
Never miss a new study
Get alerted when new AGE-RELATED MACULAR DEGENERATION (ARMD) trials appear
Sign up with your email to follow new studies for AGE-RELATED MACULAR DEGENERATION (ARMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a tiny zap save your sight? new device trial for dry AMD
Disease control Recruiting nowThis study tests a device that delivers tiny electrical pulses to the eye area for people with intermediate to advanced dry age-related macular degeneration (AMD). About 100 participants will receive either the real treatment or a sham (fake) treatment over 11 months. The goal is…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: NA • Sponsor: i-Lumen Scientific AUS PTY LTD • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New pill for macular degeneration enters first human tests
Disease control Recruiting nowThis early-stage study tests an oral drug called ABF-101 in healthy adults and people with age-related macular degeneration (AMD). The main goal is to check safety and how the body processes the drug. If successful, it could lead to a new way to control AMD, a leading cause of vi…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: PHASE1 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC